Home Health Gastric Cancer Pipeline Review, Therapeutics Development and Vaccine H1 2017

Gastric Cancer Pipeline Review, Therapeutics Development and Vaccine H1 2017

26
SHARE

The research report “Gastric Cancer – Pipeline Review, H1 2017” provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Complete research report on H1 2017 pipeline review of Gastric Cancer with 197 market data tables and 11 figures, spread across 982 pages is available at https://www.marketinsightsreports.com/reports/051811113/gastric-cancer-pipeline-review-h1-2017

Companies Involved in Therapeutics Development are 3SBio Inc, AB Science SA, AbbVie Inc, AbGenomics International Inc, Abion Inc, Adaptimmune Therapeutics Plc, ADC Therapeutics Sarl, Aduro BioTech Inc, Advaxis Inc, Advenchen Laboratories LLC, Agenus Inc, Almac Discovery Ltd, Alteogen Inc, Ambrx Inc, amcure GmbH, Amgen Inc, ANP Technologies Inc, Antikor Biopharma Ltd, arGEN-X BV, Array BioPharma Inc, Asana BioSciences LLC, Aslan Pharmaceuticals Pte Ltd, Astellas Pharma Inc, AstraZeneca Plc, Athenex Inc, Basilea Pharmaceutica Ltd, Bayer AG, BeiGene Ltd, Beijing Hanmi Pharmaceutical Co Ltd, Betta Pharmaceuticals Co Ltd, Bionovis SA, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Camel-IDS NV, Cancer Prevention Pharmaceuticals Inc, CBT Pharmaceuticals Inc, Celgene Corp, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Celltrion Inc, Celon Pharma SA, Chipscreen Biosciences Ltd, Curaxys SL, Cytori Therapeutics Inc, Daiichi Sankyo Company Ltd, Debiopharm International SA, Deciphera Pharmaceuticals LLC, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, EOS Biosciences Inc, Erytech Pharma SA, Esperance Pharmaceuticals Inc, Exelixis Inc, F-star Biotechnology Ltd, F. Hoffmann-La Roche Ltd, Five Prime Therapeutics Inc, Frost Biologic Inc, Galena Biopharma Inc, Genelux Corp, Genentech Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, GlycoNex Inc, Glycotope GmbH, Green Cross Corp, Halozyme Therapeutics Inc, Hanmi Pharmaceuticals Co Ltd, Horizon Pharma Plc, Hutchison China MediTech Ltd, Ignyta Inc, Ildong Pharmaceutical Co Ltd, Immunomedics Inc, Incyte Corp, Inovio Pharmaceuticals Inc, Inspyr Therapeutics Inc, Insys Therapeutics Inc, Intezyne Technologies Inc, Ipsen SA, Jiangsu Hengrui Medicine Co Ltd, Jiangsu Kanion Pharmaceutical Co Ltd, Johnson & Johnson, KaloBios Pharmaceuticals Inc, Kuhnil Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, LATITUDE Pharmaceuticals Inc, LegoChem Biosciences Inc, Les Laboratoires Servier SAS, MacroGenics Inc, MaxiVAX SA, Mebiopharm Co Ltd, MedImmune LLC, Merck & Co Inc, Merck KGaA, Mersana Therapeutics Inc, Merus NV, Mirati Therapeutics Inc, Molecular Partners AG, Molecular Targeting Technologies Inc, MolMed SpA, NanoCarrier Co Ltd, Novartis AG, Novogen Ltd, OBI Pharma Inc, Oncobiologics Inc, Oncolys BioPharma Inc, OncoMed Pharmaceuticals Inc, Ono Pharmaceutical Co Ltd, Opsona Therapeutics Ltd, Panacea Biotec Ltd, Patrys Ltd, Pfizer Inc, Pharma Mar SA, Plexxikon Inc, Puma Biotechnology Inc, Redx Pharma Plc, Rexahn Pharmaceuticals Inc, Rgenix Inc, Rhizen Pharmaceuticals SA, Richter Gedeon Nyrt, Samumed LLC, Sanofi, Selecta Biosciences inc, Sequella Inc, Shionogi & Co Ltd, Simcere Pharmaceutical Group, Sorrento Therapeutics Inc,Spectrum Pharmaceuticals Inc , Stelic Institute & Co Inc, Supratek Pharma Inc, SynCore Biotechnology Co Ltd, Synovo GmbH, Synthon Holdings BV, Taiho Pharmaceutical Co Ltd, Taiwan Liposome Company Ltd, Takis Srl, Tessa Therapeutics Pte Ltd, Transgene SA, United BioPharma Inc, Vaxon Biotech, Viracta Therapeutics Inc, XuanZhu Pharma Co Ltd and Zymeworks Inc.

Any questions? Feel free to reach us at https://www.marketinsightsreports.com/reports/051811113/gastric-cancer-pipeline-review-h1-2017/inquiry

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Scope of this report: The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology). The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology).

This research report will help you to:-

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

LEAVE A REPLY

Please enter your comment!
Please enter your name here